Literature DB >> 23845467

Epithelial-to-mesenchymal transition and stem cells in endometrial cancer.

Cristina Mirantes1, Iñigo Espinosa, Irene Ferrer, Xavier Dolcet, Jaime Prat, Xavier Matias-Guiu.   

Abstract

This review article describes the main features of epithelial-to-mesenchymal transition (EMT) and its possible role in understanding myometrial invasion in endometrial carcinoma (EC), as well as the development of malignant mixed Müllerian tumor (MMMT). Moreover, the article discusses the possible role of somatic (SSC) and cancer stem cells (CSC) in EC. Different transcriptional repressors of E-cadherin have been identified in EMT, including Snail and Slug, ZEB1 and ZEB2, and E47 and Twist. The expression of some of these genes is increased at the myoinvasive front and correlates inversely with E-cadherin inmunoreactivity. Whereas the transient occurrence of the EMT phenomenon is important for myometrial invasion in conventional EC, MMMT shows permanent expression of EMT leading to repression of E-cadherin and increased expression of mesenchymal markers including proteins involved in skeletal muscle development. An SSC population, identified as a side population, assessed by the Hoechst dye exclusion test has been identified in human endometrium. CSCs have been defined in analogy to SSC as cancer cells that have the capacity to self-renew, which means undergoing divisions that allow the generation of more identical CSCs and give rise to the variety of more differentiated cells found in the malignancy. Although published data show that CD133(+) cells retain the characteristics of CSC, there is no conclusive evidence showing that CD133 is the universal marker for EC stem cells. Finally, a possible role for endometrial stem cells in the development of ovarian endometriosis and ovarian endometrioid carcinoma is commented.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Endometrial carcinoma; Epithelial-to-mesenchymal transition; Somatic stem cells

Mesh:

Substances:

Year:  2013        PMID: 23845467     DOI: 10.1016/j.humpath.2013.04.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  30 in total

1.  Genetic polymorphisms in CDH1 are associated with endometrial carcinoma susceptibility among Chinese Han women.

Authors:  Yue-Hang Geng; Zi-Fan Wang; Yu-Mian Jia; Li-Yuan Zheng; Lan Chen; Dong-Ge Liu; Xiang-Hong Li; Xin-Xia Tian; Wei-Gang Fang
Journal:  Oncol Lett       Date:  2018-09-20       Impact factor: 2.967

2.  RhoC is essential in TGF-β1 induced epithelial-mesenchymal transition in cervical cancer cells.

Authors:  Xiaoqi He; Ying Qian; Huilan Cai; Shouhua Yang; Jing Cai; Zehua Wang
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

3.  A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer.

Authors:  Laura Romero-Pérez; Pablo Garcia-Sanz; Alba Mota; Susanna Leskelä; Marta Hergueta-Redondo; Juan Díaz-Martín; M Angeles López-García; M Angeles Castilla; Angel Martínez-Ramírez; Robert A Soslow; Xavier Matias-Guiu; Gema Moreno-Bueno; Jose Palacios
Journal:  Mod Pathol       Date:  2015-09-18       Impact factor: 7.842

4.  Association between Morphological Patterns of Myometrial Invasion and Cancer Stem Cell Markers in Endometrial Endometrioid Carcinoma.

Authors:  Ji Y Park; Daegy Hong; Ji Young Park
Journal:  Pathol Oncol Res       Date:  2017-10-08       Impact factor: 3.201

5.  Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

Authors:  Carlton L Schwab; Diana P English; Jonathan Black; Stefania Bellone; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Beatrice Bussi; Federica Predolini; Francesca Ferrari; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2015-08-08       Impact factor: 5.482

6.  SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.

Authors:  Gulden Menderes; Elena Bonazzoli; Stefania Bellone; Jonathan Black; Federica Predolini; Francesca Pettinella; Alice Masserdotti; Luca Zammataro; Gary Altwerger; Natalia Buza; Pei Hui; Serena Wong; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Clin Cancer Res       Date:  2017-07-05       Impact factor: 12.531

7.  Krüppel-like factor 5: a novel biomarker for lymph node metastasis and recurrence in supraglottic squamous cell laryngeal carcinoma.

Authors:  Xionghui Mao; Susheng Miao; Hongjiang He; Suping Miao; Rong Pei; Xianguang Yang; Chen Xiu; Kaibin Song; Jian Zhang; Ji Sun; Shenshan Jia; Qiang Guan
Journal:  Tumour Biol       Date:  2013-08-23

8.  Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients.

Authors:  Gaojie Liu; Jie Zhu; Menglei Yu; Canfeng Cai; Yu Zhou; Min Yu; Zhiqiang Fu; Yuanfeng Gong; Bin Yang; Yingru Li; Quanbo Zhou; Qin Lin; Huilin Ye; Liangtao Ye; Xiaohui Zhao; Zhihua Li; Rufu Chen; Fanghai Han; Chaoming Tang; Bing Zeng
Journal:  J Transl Med       Date:  2015-05-07       Impact factor: 5.531

Review 9.  EMT-Inducing Molecular Factors in Gynecological Cancers.

Authors:  Loredana Campo; Catherine Zhang; Eun-Kyoung Breuer
Journal:  Biomed Res Int       Date:  2015-08-19       Impact factor: 3.411

10.  Stem cell protein Piwil1 endowed endometrial cancer cells with stem-like properties via inducing epithelial-mesenchymal transition.

Authors:  Zheng Chen; Qi Che; Xiaoying He; Fangyuan Wang; Huihui Wang; Minjiao Zhu; Jing Sun; Xiaoping Wan
Journal:  BMC Cancer       Date:  2015-10-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.